PathAI logo

BioPharma Lab Services

Power rapid, accurate, and robust tissue-based algorithm development and deployment using PathAI’s in-house histopathology lab for research and clinical trials.

Built for Pharma Clinical Development

We create customized strategies and programs for biomarker investigation and algorithm development through our multi-disciplinary team of biomedical data scientists, pathologists, and experiences pharma execs.

Built Around AI

We’ve built a lab with a broad staining and scanning footprint across H&E, IHC, special stains, and multiplex IHC, IF, and FISH for the most robust and flexible methodologies and approaches to algorithm development and deployment.

Built for the Entire Pathology Workflow

By owning the entire pathology workflow, we have complete control over each and every sample from beginning to end, allowing us to deliver the highest level of quality, accuracy, and efficiency for research investigations and clinical trials and to adjust and optimize assays and analysis in real time.


Full anatomic and digital CAP/CLIA pathology lab for H&E, IHC, and special stains: sample receipt, processing, staining, and storage
  • 24-48 hour turnaround from slide receipt to slide digitization
  • Most commonly used WSI scanners for flexibility and customizability, including Leica, Philips, Roche, Hamamatsu, and Akoya*

  • Slide-level scoring and image analysis using our pathologist network and/or AI algorithms
  • Over 450 contracted pathologists in the PathAI network, including 20+ NASH-CRN expert pathologists

  • Assay development, optimization, and validation for immunohistochemistry (IHC), special stains, in-situ hybridization (ISH), and multiplex immunofluorescence (mIF and FISH)

    *All brand and product names are trademarks of their respective companies
    Algorithm output image of an non-small cell lung cancer sample

    Connect With Our Team

    Connect with us to learn more about how our biopharma lab services can support your end-to-end clinical trials.
    Contact Us
    physicians using a multi-scope